OBJECTIVE: The metabolic syndrome (MetSyn) predisposes to cardiovascular disease and diabetes mellitus. There might also be an association between the MetSyn and anxiety and depression, but its nature is unclear. We aimed to investigate whether diagnosis, symptom severity and antidepressant use are associated with the MetSyn. METHOD: We addressed the odds for the MetSyn and its components among 1217 depressed and/or anxious subjects and 629 controls, and their associations with symptom severity and antidepressant use. RESULTS: Symptom severity was positively associated with prevalence of the MetSyn, [adjusted odds ratio (OR) 2.21 for very severe depression: 95% confidence interval (CI): 1.06-4.64, P = 0.04], which could be attributed to abdominal obesity and dyslipidemia. Tricyclic antidepressant (TCA) use also increased odds for the MetSyn (OR 2.30, 95% CI: 1.21-4.36, P = 0.01), independent of depression severity. CONCLUSION: The most severely depressed people and TCA users more often have the MetSyn, which is driven by abdominal adiposity and dyslipidemia.
OBJECTIVE: The metabolic syndrome (MetSyn) predisposes to cardiovascular disease and diabetes mellitus. There might also be an association between the MetSyn and anxiety and depression, but its nature is unclear. We aimed to investigate whether diagnosis, symptom severity and antidepressant use are associated with the MetSyn. METHOD: We addressed the odds for the MetSyn and its components among 1217 depressed and/or anxious subjects and 629 controls, and their associations with symptom severity and antidepressant use. RESULTS: Symptom severity was positively associated with prevalence of the MetSyn, [adjusted odds ratio (OR) 2.21 for very severe depression: 95% confidence interval (CI): 1.06-4.64, P = 0.04], which could be attributed to abdominal obesity and dyslipidemia. Tricyclic antidepressant (TCA) use also increased odds for the MetSyn (OR 2.30, 95% CI: 1.21-4.36, P = 0.01), independent of depression severity. CONCLUSION: The most severely depressed people and TCA users more often have the MetSyn, which is driven by abdominal adiposity and dyslipidemia.
Authors: Nicole Vogelzangs; Aartjan T F Beekman; Arianne K B van Reedt Dortland; Robert A Schoevers; Erik J Giltay; Peter de Jonge; Brenda W J H Penninx Journal: Neuropsychopharmacology Date: 2014-01-20 Impact factor: 7.853
Authors: John S Mulvahill; Ginger E Nicol; David Dixon; Eric J Lenze; Jordan F Karp; Charles F Reynolds; Daniel M Blumberger; Benoit H Mulsant Journal: J Am Geriatr Soc Date: 2017-12 Impact factor: 5.562
Authors: Y Milaneschi; F Lamers; W J Peyrot; A Abdellaoui; G Willemsen; J-J Hottenga; R Jansen; H Mbarek; A Dehghan; C Lu; D I Boomsma; B W J H Penninx Journal: Mol Psychiatry Date: 2015-06-30 Impact factor: 15.992
Authors: Linn K Kuehl; Christoph Muhtz; Kim Hinkelmann; Lucia Dettenborn; Katja Wingenfeld; Carsten Spitzer; Christian Otte Journal: Psychopharmacology (Berl) Date: 2016-07-27 Impact factor: 4.530